Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
European Heart Journal|February 23, 2007
Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM TrialChristina Christersson, Jonas Oldgren, Anders Bylock, et al.
Drug Discovery Today|July 8, 2015
Clinical imaging in anti-atherosclerosis drug developmentAlexander Ehlgen, Anders Bylock, Jörg Kreuzer, et al.
Clinical Pharmacokinetics|January 25, 2006
Comparable pharmacokinetics and pharmacodynamics of melagatran in Japanese and caucasian volunteers after oral administration of the direct thrombin inhibitor ximelagatranLinda C Wernevik, Per Nyström, Magnus Andersson, et al.
Lancet (London, England)|September 19, 2003
Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trialLars Wallentin, Robert G Wilcox, W Douglas Weaver, et al.
Thrombosis Research|June 29, 2010
Plasma activity of individual coagulation factors, hemodilution and blood loss after cardiac surgery: a prospective observational studyLisa Ternström, Vladimir Radulovic, Martin Karlsson, et al.
Thrombosis Research|January 21, 2012
Sustained heparin effect contributes to reduced plasma thrombin generation capacity early after cardiac surgeryVladimir Radulovic, Monica Hyllner, Lisa Ternström, et al.
Thrombosis and Haemostasis|February 23, 2002
A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgeryBengt I Eriksson, Ann-Christin Arfwidsson, Lars Frison, et al.
American Heart Journal|January 25, 2008
Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trialMarco J D Tangelder, Lars Frison, Douglas Weaver, et al.
Clinical Drug Investigation|May 26, 2007
Postoperative Melagatran/Ximelagatran for the Prevention of Venous Thromboembolism following Major Elective Orthopaedic Surgery : Effects of Timing of First Dose and Risk Factors for Thromboembolism and Bleeding Complications on Efficacy and SafetyOla E Dahl, Bengt I Eriksson, Giancarlo Agnelli, et al.
Thrombosis and Haemostasis|March 10, 2006
Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis modelKarin Wåhlander, Maria Eriksson-Lepkowska, Per Nyström, et al.
Pageof 2